Skip to content
‹ Back to IndustriesHealthcare

Weighing the Risks of AI Tools, From Demographic Bias to Privacy Violations

With Microsoft announcing a multibillion dollar investment into ChatGPT, Google launching Bard, and China’s search engine giant Baidu, Inc. entering the race with Ernie, the AI party has officially begun. More companies are integrating ChatGPT into their daily operations as the tool proves itself as flexible for a variety of use cases, and adoption…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

With Microsoft announcing a multibillion dollar investment into ChatGPT, Google launching Bard, and China’s search engine giant Baidu, Inc. entering the race with Ernie, the AI party has officially begun. More companies are integrating ChatGPT into their daily operations as the tool proves itself as flexible for a variety of use cases, and adoption is hot; the number of users on ChatGPT crossed 100 million over a month ago. However, even with all this use case validation and excitement around generative AI’s possibilities, experts are increasingly warning against the risks of AI.

Recently, the Federal Trade Commission (FTC) warned companies against making baseless claims and failing to see the risks posed by their AI-enabled products. The warning comes nearly two years after the FTC had raised concerns about the “troubling outcomes” produced by some AI tools. Here, the FTC pointed out how an algorithm in the healthcare industry was found to show racial bias. And a few years ago, Amazon found that its recruiting tool discriminated against women.

In the past, the FTC has fined Facebook billions of dollars for violating users’ privacy through its facial recognition software. Even White Castle, a hamburger chain, could face a fine worth billions of dollars for the automated collection and sharing of the biometric data of its employees without prior consent.

Scott Sereboff, the general manager for the North American for Deeping Source, a spatial analytics company that offers software for businesses to collect physical and virtual data without infringing on individual customers’ or employees’ privacy, gives his perspectives on the risks of AI and why he has been on a campaign to highlight its ethical uses.

Scott’s Thoughts:

“When it comes to artificial intelligence, machine learning and the things that go with it, perhaps the key topic on which industry thought leaders should be focused is ethics and morality, and where we’re going with this and how we’re going to use it. The benefits of AI and machine learning are probably too numerous to count, but are we letting it grow past our ability to guide and shape it into something that is at least more difficult to use in a negative way. The conversations that all these industry experts should be having are around that — demystifying AI and machine learning, helping people to understand that at the end of every one of these algorithmic chains is a human who has either programmed it or categorized the data or has had a hand in determining the shaping of a database or of the AI itself. The part of this process that becomes scary is if we can write the ultimate AI for good programming in any subset (facial recognition, voice recognition), so too can a bad person write the fascist version or the apartheid version. IBM assisted the South African government in the creation of a database that was used for the suppression of black South Africans.

Now with every part of the AI development process, there’s something important consider in light of how it is or is not regulated. In the United States, we don’t really have a specified GDPR-style legislation. Illinois has an incredibly tough legislation, however and California too.

Another discussion we should really be having is about potential legal ramifications. Are you and your company protected against the potential legal trouble you can find yourself in if you reveal personal information or take personal information from a person without his/her permission? It is a legal gray area but are we paying enough attention to that topic as well?

Let’s say I’m running a multistage corporation that has front-end retail or shopping or a hospital network and I’ve got some sort of AI that is collecting data through video cameras or audio interfaces or gate analysis. The questions I must ask is: am I paying attention to whether or not this can be used to track everything back to me?

I don’t know if everyone realizes the potential danger and with what just happened in Illinois with the White Castle case, although it’s certainly — I should say, almost certainly — not going to wind up as bad as it is right now. The industry’s response to it has been one of surprise, and yet, why are they surprised?

We have spent decades watching social media become this incredibly divisive sort of societal upheaval mechanism. If we’re not careful and we don’t keep an eye on what we’re doing with artificial intelligence, it will do exactly the same thing and history will repeat itself. It’s really easy to say, ‘I’m not prejudiced. The database made me do it.’ So I would suggest that across all of the three questions you’ve asked, the key topics, important conversations, important questions, are all questions around morality and ethics.”

Article written by Aarushi Maheswhari

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

New York City digital health startups raised $1.9 billion in Q3, up 36%

New York City digital health startups raised $1.9 billion in Q3, up 36%

New York City digital health startups raised $1.9 billion in Q3 2026, up 36% year over year. Nationally, Rock Health counted $3.7 billion raised by U.S. digital health startups across 114 deals in the quarter. Bigger checks and steady acquisitions mean buyers must assess which vendors are pulling ahead—and which may change owners mid-rollout.

  • 01New York's digital health startups grew Q3 funding 36% year over year, while U.S. digital health startups raised $3.7 billion across 114 deals in Q3, according to Rock Health.
  • 02Average U.S. digital health deal size has climbed from $20.6 million in 2024 to $31.0 million so far in 2026, so more of the money is going into bigger rounds.
  • 03Acquisition is still how most digital health companies exit, with 164 deals through Q3 2026 and no new public listings since August 2025. That makes a vendor's change-of-ownership terms a live contract question for buyers.

Nov 4, 2026

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS said on November 3 it acquired LookDeep Health, a computer vision company, and introduced iQueue for Virtual Care, its first product built on what it calls ambient intelligence. Terms were not disclosed. The product bundles Virtual Observation, Virtual Nursing and Virtual Medicine, and LeanTaaS says hospitals can build on compatible cameras and in-room devices already installed or deploy supported hardware. The company cited reported results from LookDeep deployments, including fall-rate reductions of more than 70%, and said LookDeep's technology was evaluated in peer-reviewed research published in Frontiers in Imaging.

  • 01LeanTaaS acquired LookDeep Health and launched iQueue for Virtual Care, combining Virtual Observation, Virtual Nursing and Virtual Medicine; acquisition terms were not disclosed.
  • 02Hospitals can build on compatible cameras and in-room devices already in place or deploy supported hardware, according to LeanTaaS, which did not name camera vendors.
  • 03LeanTaaS reported results from LookDeep deployments including fall-rate reductions of more than 70% and twice as much nursing contact, figures that are the company's own and not tied to named health systems.

Nov 3, 2026

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Royal Philips reported 8% comparable order intake growth for the third quarter of 2026, driven by Diagnosis & Treatment, with comparable sales up 3% to EUR 4.4 billion and an adjusted EBITA margin of 13.0%, up 70 basis points. The company reiterated its 2026 outlook for 3% to 4.5% comparable sales growth. Philips Respironics reached an agreement in principle with the US Department of Justice to resolve previously disclosed investigations related to its recall, and Philips recorded a EUR 288 million provision in the quarter, with payment expected in the first quarter of 2027 subject to final documentation.

  • 01Comparable order intake grew 8%, matching a year earlier, with Diagnosis & Treatment the driver; the equipment order book stands at about 40% of revenue.
  • 02Comparable sales rose 3% to EUR 4.4 billion, adjusted EBITA margin reached 13.0%, and free cash flow was EUR 384 million; the 2026 outlook was reiterated.
  • 03Philips Respironics reached an agreement in principle with the DOJ on previously disclosed recall investigations, and Philips recorded a EUR 288 million provision; the settlement is subject to final documentation.

Nov 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512